Does prophylactic N-AcetylCysteine decrease incidence of contrast nephropathy in patients undergoing peripheral angiography?

Completed

• Conditions: Contrast induced nephropathy; Urological and Genital Diseases; Nephropathy

• Registration Number: ISRCTN35882618
• Lead Sponsor: Cambridge University Hospital NHS Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-08-02
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 40

Inclusion Criteria

Any patient undergoing peripheral angiography in the Cambridge Vascular Unit, Addenbrooke?s Hospital, Cambridge who consents to participation.

Exclusion Criteria

1. Any patient undergoing peripheral angiography in Cambridge Vascular Unit
2. Any patient that does not consent to participation in the study
3. Any patient under the age of 18 years
4. Any patient with established renal failure on renal replacement therapy (dialysis)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primarily we are looking for a reduction in the elevation in Albumin/Creatinine ratio and also of other markers of renal damage in urine (retinol binding protein), using the samples collected before the angiogram and first, second and third day post angiography.

Secondary Outcome Measures

Name	Time	Method
A reduction in the mortality and morbidity related to renal failure that may result secondary to contrast solution used in angiography; this 30-day mortality morbidity reduction will be measured on follow up in clinic normally four to six weeks post angiography.